The sixth iteration of this conference will feature a diverse mix of professionals from the global captive industry KUALA LUMPUR, Malaysia, Aug. 22, 2023 /PRNewswire/ Labuan IBFC Incorporated Sdn Bhd (Labuan IBFC Inc.) will co-host the ASIAN CAPTIVE CONFERENCE (ACC) 2023 with Labuan International Insurance Association (LIIA) on 7 September 2023 at the Sime Darby Convention Centre in Kuala Lumpur, Malaysia. Themed The Connected Risk Journey in Self-Insurance, this in-person conferenceaims to help professionals navigate their risk journey at critical touchpoints in the ever-shifting risk landscape. This conference will provide a platform for stakeholders across all segments in the global captive market. Datuk Iskandar Mohd Nuli, Executive Chairman cum CEO of Labuan IBFC Inc. will deliver the welcome address while En. Nik Mohamed Din Nik Musa, Director General of Labuan Financial Services Authority (Labuan FSA) will officiate the ceremony. As at December 2022, the Labuan captive industr
BANGKOK, Aug. 22, 2022 /PRNewswire/ Mondelez International (Thailand) Co., Ltd. ("Mondelez International") is among 18 elite award recipients of Asia Pacific Enterprise Awards 2022 Thailand Chapter which were presented by Enterprise Asia, a leading regional non-governmental organization for entrepreneurship. Organized by Enterprise Asia, a leading regional non-governmental organization for entrepreneurship, the Asia Pacific Enterprise Awards is held annually across 16 countries and markets and is the most reputable award recognition program recognizing entrepreneurial excellence across Asia. The aim of the award is to congregate outstanding business leaders and enterprises across Asia into one unparalleled platform for fostering the continuity of sustainable entrepreneurial growth in Asian economies. Mondelez International is one of the largest snack companies in the world with net revenues of approximately USD28.7 billion and operates in over 150 countries. One of Mondelez&
Novavax' vaccine is the first protein-based COVID-19 vaccine authorized in the U.S. Doses of the Novavax COVID-19 Vaccine, Adjuvanted are now available and primary series immunizations for adolescents can begin once a policy recommendation from the CDC is received GAITHERSBURG, Md., Aug. 22, 2022 /PRNewswire/ Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the Novavax COVID-19 Vaccine, Adjuvanted(NVX-CoV2373) has received expanded emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) to provide a two-dose primary series for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in adolescents aged 12 through 17. "Having more vaccine options for use in both adults and adolescents, like the Novavax COVID-19 Vaccine, Adjuvanted will hopefull